TY  - JOUR

T1  - Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

JO  - Health Technol Assess

PY  - 2012/10/01

AU  - Papaioannou D

AU  - Rafia R

AU  - Rathbone J

AU  - Stevenson M

AU  - Buckley Woods H

AU  - Stevens J

ED  - 

DO  - DOI: 10.3310/hta16370

VL  - 16

IS  - 37

SP  - 1

EP  - iv

Y2  - 2024/12/22

ER  -